Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Roivant Sciences (ROIV) EBT Margin (2020 - 2025)

Roivant Sciences' EBT Margin history spans 6 years, with the latest figure at 14525.71% for Q4 2025.

  • For Q4 2025, EBT Margin fell 1192521.0% year-over-year to 14525.71%; the TTM value through Dec 2025 reached 16606.06%, down 3836750.0%, while the annual FY2025 figure was 2346.02%, 1630945.0% down from the prior year.
  • EBT Margin reached 14525.71% in Q4 2025 per ROIV's latest filing, down from 10123.74% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 33116.21% in Q4 2023 to a low of 14525.71% in Q4 2025.
  • Average EBT Margin over 5 years is 2462.91%, with a median of 2503.44% recorded in 2022.
  • Peak YoY movement for EBT Margin: surged 3535687bps in 2023, then tumbled -3571671bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 1257.33% in 2021, then tumbled by -78bps to 2240.66% in 2022, then skyrocketed by 1578bps to 33116.21% in 2023, then crashed by -108bps to 2600.5% in 2024, then plummeted by -459bps to 14525.71% in 2025.
  • Per Business Quant, the three most recent readings for ROIV's EBT Margin are 14525.71% (Q4 2025), 10123.74% (Q3 2025), and 12408.39% (Q2 2025).